Solventum (SOLV) stock: analyst price target and their real reliability
Live quote · data updated Oct 14, 2026
Solventum · Health Care · ref. ETF XLV · 50 calls · price $86.3
What the company does: Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally.
📈 Solventum (SOLV) stock price
$86.3+20.7% over range
Oct 14, 25low $62.49 · high $92.44Oct 13, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
75% recommend buying · 8 analysts
📊 JPI status : Solventum has never appeared in a JPI ranking (Fair or Risk +) — our methods haven't picked it to date. See the selected stocks →
🎯 SOLV price target & analyst consensus — price $86.30
The price target · all analysts combined (8 targets)
Highest target · 1 firm of 8$105+21.7%
Median target · of 8 targets$100.5+16.5%
Lowest target · 1 firm of 8$70-18.9%
Current price$86.3
Where these 8 targets sit · versus the current price · 1 target per firm, last 6 months
Above the price
675%
$95 ↔ $105
Below
225%
$70 ↔ $81
⭐ What the most reliable analysts say
· those who beat their sector, targets replayed on real prices
⭐ The most reliable of them, either direction: Stifel — 68% of its targets hit on this sector (304 calls tested). It aims for $100 (+16 %), call made on August 7, 2026, maturing on August 7, 2027 (68 d ago).
The 4 reliable analysts
$101+16 %
The 4 other firms
$91+5.4 %
How to read it: the 4 reliable firms are not filtered by optimism — 4 aim above the price, 0 below, hence their $101 median. “The 4 others” are the firms that don't pass our reliability filter on this sector.
The consensus · 8 ratings (last 6 months)
Strong Buy00%
Buy675%
Hold225%
Sell00%
Strong Sell00%
Go deeper on the analysts
🎯 SOLV price target all
All 50 calls, one by one, with our verdict on each firm.
→ See all 50 targets, analyst by analyst💡 The best analysts on SOLV most reliable
The case for and against, with the numbers, per those who've been right on the stock.
→ Should you invest in SOLV? The case for & againstAll analysts (the consensus) · vs · the best (those who've been right)
💬 A question about Solventum? The JPI assistant answers using our backtest data.
📈 Solventum fundamentals: valuation, margins & growth › open the full page
P/E 10.4Net margin 17.3 %Revenue growth +2.2 %Low P/E
Revenue, net income and margin per year
Revenue Net income · hover a bar for details
2023
2024
Profit −64%
2025
Rev +1%Profit +225%
🔎 Detailed analyses
✅ Historical analyst reliability on SOLV
Hit rate measured on targets already matured (12 months), replayed against real prices. Click a header to sort.
| Firm ↕ | % right i ↕ | Gain vs sector i ↕ | Calls i ↕ |
|---|---|---|---|
| Piper Sandler ↗ | 100% | +9.0% | 2 |
| Goldman Sachs ↗ | 25% | -22.9% | 4 |
📊 What $1,000 invested in Solventum would be worth › open the full page
In short — $1,000 invested in Solventum 10 years ago would be worth $1,109 today, i.e. +5%/yr on average. Best year: 2025 (+18%), worst: 2025 (+18%). Price performance, excluding dividends.
If I'd invested $1,000 in Solventum
| Investment | Worth today | Gain |
|---|---|---|
| 1 years ago | $1,149 | +15% |
Return by year (Solventum)
| Year | Return | $1,000 invested at year start |
|---|---|---|
| 2026 (YTD) | -2% | $976 (-2%) |
| 2025 | +18% | $1,149 (+15%) |
⚠️ Past performance, not predictive nor advice. Prices in $, excluding dividends. Yahoo Finance data.
📰 Recent news on Solventum
Loading news…
📋 All analyst calls on SOLV
Filtered on — · ✕ show all
▲ Buy · 🎯$95
Price at call : $89.82 — upside +6%
Today : $86.3 — upside +10%
🎯 on SOLV : no call matured yet · 📊 on Health : 51.2% · +5.3% (123 calls)
in progress (365j)
matures : Sep 14, 27
matures : Sep 14, 27
▲ Buy · 🎯$101
Price at call : $82.98 — upside +22%
Today : $86.3 — upside +17%
🎯 on SOLV : no call matured yet · 📊 on Health : 51.7% · +3.1% (358 calls)
in progress (365j)
matures : Aug 6, 27
matures : Aug 6, 27
Piper Sandler ↗
Aug 6, 26
▲ Overweight · 🎯$105
Price at call : $82.98 — upside +27%
Today : $86.3 — upside +22%
🎯 on SOLV : 100% (2 calls matureds) · 📊 on Health : 46.6% · -1.4% (324 calls)
in progress (365j)
matures : Aug 6, 27
matures : Aug 6, 27
▲ Outperform · 🎯$101
Price at call : $82.98 — upside +22%
Today : $86.3 — upside +17%
🎯 on SOLV : no call matured yet · 📊 on Health : 42.9% · -6.3% (7 calls)
in progress (365j)
matures : Aug 6, 27
matures : Aug 6, 27
▲ Overweight · 🎯$102
Price at call : $82.98 — upside +23%
Today : $86.3 — upside +18%
🎯 on SOLV : no call matured yet · 📊 on Health : 43.4% · -1.8% (145 calls)
in progress (365j)
matures : Aug 6, 27
matures : Aug 6, 27
▲ Buy · 🎯$100
Price at call : $82.98 — upside +21%
Today : $86.3 — upside +16%
🎯 on SOLV : 100% (1 call matured) · 📊 on Health : 50.7% · +7.8% (304 calls)
in progress (365j)
matures : Aug 6, 27
matures : Aug 6, 27
▲ Buy · 🎯$95
Price at call : $82.96 — upside +15%
Today : $86.3 — upside +10%
🎯 on SOLV : no call matured yet · 📊 on Health : 51.2% · +5.3% (123 calls)
in progress (365j)
matures : Aug 6, 27
matures : Aug 6, 27
▲ Buy · 🎯$95
Price at call : $88.55 — upside +7%
Today : $86.3 — upside +10%
🎯 on SOLV : no call matured yet · 📊 on Health : 51.7% · +3.1% (358 calls)
in progress (365j)
matures : Jul 28, 27
matures : Jul 28, 27
See the other 42 calls, newest to oldest
BMO Capital ↗
Jul 9, 26
■ Market Perform neutral · not a buy · 🎯$81
Price at call : $76.7 — gap to target +6%
Today : $86.3 — gap to target -6%
🎯 on SOLV : no call matured yet · 📊 on Health : 60.4% · +8.8% (240 calls)
in progress (365j)
matures : Jul 9, 27
matures : Jul 9, 27
▲ Outperform · 🎯$94
Price at call : $76.13 — upside +23%
Today : $86.3 — upside +9%
🎯 on SOLV : no call matured yet · 📊 on Health : 42.9% · -6.3% (7 calls)
in progress (365j)
matures : May 15, 27
matures : May 15, 27
■ Neutral neutral · not a buy · 🎯$78
Price at call : $71.65 — gap to target +9%
Today : $86.3 — gap to target -10%
🎯 on SOLV : no call matured yet · 📊 on Health : 51.7% · +3.1% (358 calls)
in progress (365j)
matures : May 6, 27
matures : May 6, 27
▲ Buy · 🎯$90
Price at call : $71.65 — upside +26%
Today : $86.3 — upside +4%
🎯 on SOLV : 100% (1 call matured) · 📊 on Health : 50.7% · +7.8% (304 calls)
in progress (365j)
matures : May 6, 27
matures : May 6, 27
Wells Fargo ↗
May 6, 26
■ Equal-Weight neutral · not a buy · 🎯$70
Price at call : $71.65 — gap to target -2%
Today : $86.3 — gap to target -19%
🎯 on SOLV : no call matured yet · 📊 on Health : 47.6% · +1.0% (403 calls)
in progress (365j)
matures : May 6, 27
matures : May 6, 27
▲ Overweight · 🎯$93
Price at call : $70.99 — upside +31%
Today : $86.3 — upside +8%
🎯 on SOLV : no call matured yet · 📊 on Health : 43.4% · -1.8% (145 calls)
in progress (365j)
matures : May 6, 27
matures : May 6, 27
▲ Buy · 🎯$89
Price at call : $70.99 — upside +25%
Today : $86.3 — upside +3%
🎯 on SOLV : no call matured yet · 📊 on Health : 51.2% · +5.3% (123 calls)
in progress (365j)
matures : May 6, 27
matures : May 6, 27
▲ Overweight · 🎯$92
Price at call : $67.51 — upside +36%
Today : $86.3 — upside +7%
🎯 on SOLV : no call matured yet · 📊 on Health : 43.4% · -1.8% (145 calls)
in progress (365j)
matures : Apr 27, 27
matures : Apr 27, 27
Piper Sandler ↗
Apr 17, 26
▲ Overweight · 🎯$92
Price at call : $70.04 — upside +31%
Today : $86.3 — upside +7%
🎯 on SOLV : 100% (2 calls matureds) · 📊 on Health : 46.6% · -1.4% (324 calls)
in progress (365j)
matures : Apr 17, 27
matures : Apr 17, 27
Rothschild & Co
Mar 24, 26
▼ Sell · 🎯$60
Price at call : $64.03 — upside -6%
Today : $86.3 — upside -30%
🎯 on SOLV : no call matured yet · 📊 unranked overall
in progress (365j)
matures : Mar 24, 27
matures : Mar 24, 27
Wells Fargo ↗
Feb 27, 26
■ Equal-Weight neutral · not a buy · 🎯$83
Price at call : $73 — gap to target +14%
Today : $86.3 — gap to target -4%
🎯 on SOLV : no call matured yet · 📊 on Health : 47.6% · +1.0% (403 calls)
in progress (365j)
matures : Feb 27, 27
matures : Feb 27, 27
▲ Overweight · 🎯$99
Price at call : $74.2 — upside +33%
Today : $86.3 — upside +15%
🎯 on SOLV : no call matured yet · 📊 on Health : 43.4% · -1.8% (145 calls)
in progress (365j)
matures : Feb 27, 27
matures : Feb 27, 27
▲ Buy · 🎯$100
Price at call : $74.2 — upside +35%
Today : $86.3 — upside +16%
🎯 on SOLV : no call matured yet · 📊 on Health : 51.2% · +5.3% (123 calls)
in progress (365j)
matures : Feb 27, 27
matures : Feb 27, 27
▲ Overweight · 🎯$97
Price at call : $79.01 — upside +23%
Today : $86.3 — upside +12%
🎯 on SOLV : no call matured yet · 📊 on Health : 43.4% · -1.8% (145 calls)
in progress (365j)
matures : Jan 26, 27
matures : Jan 26, 27
▲ Outperform · 🎯$100
Price at call : $78.96 — upside +27%
Today : $86.3 — upside +16%
🎯 on SOLV : no call matured yet · 📊 on Health : 51.4% · +3.4% (222 calls)
in progress (365j)
matures : Jan 20, 27
matures : Jan 20, 27
▲ Buy · 🎯$105
Price at call : $84.24 — upside +25%
Today : $86.3 — upside +22%
🎯 on SOLV : 100% (1 call matured) · 📊 on Health : 50.7% · +7.8% (304 calls)
in progress (365j)
matures : Jan 7, 27
matures : Jan 7, 27
▲ Buy · 🎯$100
Price at call : $85.59 — upside +17%
Today : $86.3 — upside +16%
🎯 on SOLV : no call matured yet · 📊 on Health : 51.2% · +5.3% (123 calls)
in progress (365j)
matures : Dec 2, 26
matures : Dec 2, 26
■ Neutral neutral · not a buy · 🎯$79
Price at call : $73.88 — gap to target +7%
Today : $86.3 — gap to target -8%
🎯 on SOLV : no call matured yet · 📊 on Health : 51.7% · +3.1% (358 calls)
in progress (365j)
matures : Nov 10, 26
matures : Nov 10, 26
Piper Sandler ↗
Nov 7, 25
▲ Overweight · 🎯$98
Price at call : $71.52 — upside +37%
Today : $86.3 — upside +14%
🎯 on SOLV : 100% (2 calls matureds) · 📊 on Health : 46.6% · -1.4% (324 calls)
in progress (365j)
matures : Nov 7, 26
matures : Nov 7, 26
■ Neutral neutral · not a buy · 🎯$77
Price at call : $73.04 — gap to target +5%
Today : $86.3 — gap to target -11%
🎯 on SOLV : no call matured yet · 📊 on Health : 51.7% · +3.1% (358 calls)
in progress (365j)
matures : Oct 1, 26
matures : Oct 1, 26
Wells Fargo ↗
Sep 15, 25
■ Equal-Weight neutral · not a buy · 🎯$82
Price at call : $74.13 — gap to target +11%
Today : $86.3 — gap to target -5%
🎯 on SOLV : no call matured yet · 📊 on Health : 47.6% · +1.0% (403 calls)
in progress (365j)
matures : Sep 15, 26
matures : Sep 15, 26
■ Hold neutral · not a buy · 🎯$80
Price at call : $73.79 — gap to target +8%
Today : $86.3 — gap to target -7%
🎯 on SOLV : no call matured yet · 📊 on Health : 51.2% · +4.7% (383 calls)
in progress (365j)
matures : Sep 11, 26
matures : Sep 11, 26
Wells Fargo ↗
Aug 8, 25
■ Equal-Weight neutral · not a buy · 🎯$79
Price at call : $71.86 — gap to target +10%
Today : $86.3 — gap to target -8%
🎯 on SOLV : no call matured yet · 📊 on Health : 47.6% · +1.0% (403 calls)
in progress (365j)
matures : Aug 8, 26
matures : Aug 8, 26
Piper Sandler ↗
Aug 8, 25
▲ Overweight · 🎯$94
Price at call : $73.39 — upside +28%
Today : $86.3 — upside +9%
Expected +28% · Actual +16% · Reason (≥ +15%) : ✓ Yes
🎯 on SOLV : 100% (2 calls matureds) · 📊 on Health : 46.6% · -1.4% (324 calls)
+16.1%
stock +16% · XLV +29%
matured Aug 8, 26
Morgan Stanley ↗
Jul 15, 25
▲ Overweight · 🎯$103
Price at call : $73.68 — upside +40%
Today : $86.3 — upside +19%
Expected +40% · Actual +6% · Reason (≥ +15%) : ✗ No
🎯 on SOLV : 100% (1 call matured) · 📊 on Health : 51.6% · +5.2% (830 calls)
+6.4%
stock +6% · XLV +19%
matured Jul 15, 26
Argus Research ↗
Jul 1, 25
▲ Buy
Actual +0% · Reason (≥ +15%) : ✗ No
🎯 on SOLV : 100% (1 call matured) · 📊 on Health : 55.3% · +2.1% (159 calls)
+0.0%
stock +0% · XLV +21%
matured Jul 1, 26
■ Sector Weight neutral · not a buy
🎯 on SOLV : no call matured yet · 📊 on Health : 43.4% · -1.8% (145 calls)
in progress (365j)
matures : Jun 6, 26
matures : Jun 6, 26
Piper Sandler ↗
May 19, 25
▲ Overweight · 🎯$87
Price at call : $74.7 — upside +16%
Today : $86.3 — upside +1%
Expected +16% · Actual +2% · Reason (≥ +15%) : ✗ No
🎯 on SOLV : 100% (2 calls matureds) · 📊 on Health : 46.6% · -1.4% (324 calls)
+1.9%
stock +2% · XLV +9%
matured May 19, 26
Piper Sandler ↗
May 9, 25
■ Neutral neutral · not a buy · 🎯$78
Price at call : $74.8 — gap to target +4%
Today : $86.3 — gap to target -10%
🎯 on SOLV : 100% (2 calls matureds) · 📊 on Health : 46.6% · -1.4% (324 calls)
in progress (365j)
matures : May 9, 26
matures : May 9, 26
Piper Sandler ↗
Apr 30, 25
■ Neutral neutral · not a buy · 🎯$80
Price at call : $65.62 — gap to target +22%
Today : $86.3 — gap to target -7%
🎯 on SOLV : 100% (2 calls matureds) · 📊 on Health : 46.6% · -1.4% (324 calls)
in progress (365j)
matures : Apr 30, 26
matures : Apr 30, 26
Morgan Stanley ↗
Mar 5, 25
■ Equal-Weight neutral · not a buy · 🎯$80
Price at call : $77.83 — gap to target +3%
Today : $86.3 — gap to target -7%
🎯 on SOLV : 100% (1 call matured) · 📊 on Health : 51.6% · +5.2% (830 calls)
in progress (365j)
matures : Mar 5, 26
matures : Mar 5, 26
■ Neutral neutral · not a buy · 🎯$82
Price at call : $78.99 — gap to target +4%
Today : $86.3 — gap to target -5%
🎯 on SOLV : no call matured yet · 📊 on Health : 51.4% · +3.4% (222 calls)
in progress (365j)
matures : Mar 3, 26
matures : Mar 3, 26
Goldman Sachs ↗
Mar 3, 25
▼ Sell · 🎯$71
Price at call : $78.99 — upside -10%
Today : $86.3 — upside -18%
Expected -10% · Actual -11% · Reason (≤ −15%) : ✗ No
🎯 on SOLV : 100% (1 call matured) · 📊 on Health : 51.4% · +2.3% (243 calls)
+10.9%
stock -11% · XLV +6%
matured Mar 3, 26
Wells Fargo ↗
Feb 28, 25
■ Equal-Weight neutral · not a buy · 🎯$75
Price at call : $80.16 — gap to target -6%
Today : $86.3 — gap to target -13%
🎯 on SOLV : no call matured yet · 📊 on Health : 47.6% · +1.0% (403 calls)
in progress (365j)
matures : Feb 28, 26
matures : Feb 28, 26
Piper Sandler ↗
Feb 28, 25
■ Neutral neutral · not a buy · 🎯$84
Price at call : $79.75 — gap to target +5%
Today : $86.3 — gap to target -3%
🎯 on SOLV : 100% (2 calls matureds) · 📊 on Health : 46.6% · -1.4% (324 calls)
in progress (365j)
matures : Feb 28, 26
matures : Feb 28, 26
B of A Securities ↗
Feb 26, 25
■ Neutral neutral · not a buy · 🎯$85
Price at call : $84.04 — gap to target +1%
Today : $86.3 — gap to target -2%
🎯 on SOLV : no call matured yet · 📊 on Health : 48.1% · +2.0% (362 calls)
in progress (365j)
matures : Feb 26, 26
matures : Feb 26, 26
■ Neutral neutral · not a buy · 🎯$70
Price at call : $70.26 — gap to target -0%
Today : $86.3 — gap to target -19%
🎯 on SOLV : no call matured yet · 📊 on Health : 51.4% · +3.4% (222 calls)
in progress (365j)
matures : Dec 4, 25
matures : Dec 4, 25
Morgan Stanley ↗
Nov 11, 24
■ Equal-Weight neutral · not a buy · 🎯$73
Price at call : $71.53 — gap to target +2%
Today : $86.3 — gap to target -15%
🎯 on SOLV : 100% (1 call matured) · 📊 on Health : 51.6% · +5.2% (830 calls)
in progress (365j)
matures : Nov 11, 25
matures : Nov 11, 25
Piper Sandler ↗
Nov 8, 24
■ Neutral neutral · not a buy · 🎯$75
Price at call : $72.43 — gap to target +4%
Today : $86.3 — gap to target -13%
🎯 on SOLV : 100% (2 calls matureds) · 📊 on Health : 46.6% · -1.4% (324 calls)
in progress (365j)
matures : Nov 8, 25
matures : Nov 8, 25
▲ Buy · 🎯$82
Price at call : $67.13 — upside +22%
Today : $86.3 — upside -5%
Expected +22% · Actual +8% · Reason (≥ +15%) : ✗ No
🎯 on SOLV : 100% (1 call matured) · 📊 on Health : 50.7% · +7.8% (304 calls)
+7.9%
stock +8% · XLV -5%
matured Oct 8, 25
Piper Sandler ↗
Oct 7, 24
■ Neutral neutral · not a buy · 🎯$71
Price at call : $66.29 — gap to target +7%
Today : $86.3 — gap to target -18%
🎯 on SOLV : 100% (2 calls matureds) · 📊 on Health : 46.6% · -1.4% (324 calls)
in progress (365j)
matures : Oct 7, 25
matures : Oct 7, 25
Wolfe Research ↗
Sep 26, 24
■ Peer Perform neutral · not a buy
🎯 on SOLV : no call matured yet · 📊 on Health : 60.9% · +4.3% (46 calls)
in progress (365j)
matures : Sep 26, 25
matures : Sep 26, 25
Frequently asked questions
Should I buy Solventum stock?
This isn't buy advice. For Solventum, the analyst consensus is "Buy", with an average price target of $101 (+16% vs the current price). What matters is their past reliability on this stock: the most reliable one is right 100% of the time (2 calls tracked on Solventum). We show the numbers — you decide.
Is it too late to buy Solventum? How high can it go?
The most bullish analyst target on Solventum is $105 (+22% above today's price); the average is $101. That's the upside they see. Check how reliable those analysts have actually been on Solventum on our site before trusting it.
Is Solventum still a good buy?
The most useful "opinion" isn't an opinion — it's a track record: 2 analysts have a real record on Solventum, the best hitting 100% over 2 calls. Current consensus: "Buy". Make your call on data, not noise.
Should you invest in Solventum? The case for and against
The arguments for and against, one by one, from the numbers: why invest in SOLV (and why hesitate).
What has Solventum's past performance been?
Historical returns and a "how much if I had invested" calculator: SOLV performance & returns.
BIIB 
VRTX 
REGN 
UNH 
EW 
SRPT 
VEEV 
BSX